The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...

Abbott (NYSE: ABT) received FDA clearance for its Amplatzer Piccolo delivery system for use with the Amplatzer Piccolo ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system ...

Abbott has secured the US Food and Drug Administration (FDA) and CE Mark approvals for its Amplatzer Piccolo delivery system, ...

Abbott ABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the ...

New Guidelines Issued for Management of Atrial Fibrillation The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology. Using dual-seal ...

Abbott Laboratories’ Amplatzer Amulet left atrial appendage (LAA) occlusion device has been shown at one year to reduce stroke by 57% as compared to the predicted stroke risk. The data also showed it ...

Abbott Laboratories (NYSE:ABT) is recalling the Amplatzer Steerable Delivery Sheath due to an increased risk for air bubbles (air emboli) to be introduced into patients who have procedures with this ...

ST. PAUL, Minn. -- St. Jude Medical, Inc., a global medical device company, today announced it has received U.S. Food and Drug Administration (FDA) clearance and will immediately launch the AMPLATZER™ ...

Abbott is recalling the Amplatzer steerable delivery sheath, used to deliver the Amplatzer Amulet left atrial appendage occluder during cardiac catheterization, because of an increased risk of air ...

The Amplatzer Piccolo device is inserted through a small incision in the infant's leg and guided through vessels to the heart using the Amplatzer Piccolo Delivery System, where it is placed to seal ...